CD33+/HLA-DRneg and CD33+/HLA-DR+/– cells: Rare populations in the human decidua with characteristics of MDSC

American Journal of Reproductive Immunology

Volumn 75, Issue 5, 2016, Pages 539-556

  Bartmann, Catharina ^a   Junker, Markus ^a   Segerer, Sabine E ^b   Häusler, Sebastian F ^a   Krockenberger, Mathias ^a   Kämmerer, Ulrike ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b ENDOKRINOLOGIKUM HAMBURG   (Germany)

Author keywords

CD33; Decidua; Human pregnancy; Immune tolerance; MDSC

Indexed keywords

ARGINASE; CD33 ANTIGEN; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CELL ISOLATION; CELL SUBPOPULATION; COCULTURE; CONTROLLED STUDY; DECIDUA; FEMALE; FIRST TRIMESTER PREGNANCY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LYMPHOCYTE PROLIFERATION; MICROSCOPY; MYELOID-DERIVED SUPPRESSOR CELL; NORMAL HUMAN; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING; CELL CULTURE; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; COCULTURE TECHNIQUES; DECIDUA; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; MYELOID-DERIVED SUPPRESSOR CELLS; PREGNANCY; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES, REGULATORY;

EID: 84956965081     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12492     Document Type: Article

References (101)

1. Bartmann C, Segerer SE, Rieger L, Kapp M, Sutterlin M, Kammerer U: Quantification of the predominant immune cell populations in decidua throughout human pregnancy. Am J Reprod Immunol 2014; 71:109–119.
2. Bulmer JN, Williams PJ, Lash GE: Immune cells in the placental bed. Int J Dev Biol 2010; 54:281–294.
3. Loke YW, King A, Burrows TD: Decidua in human implantation. Hum Reprod 1995; 10(Suppl 2):14–21.
4. Trundley A, Moffett A: Human uterine leukocytes and pregnancy. Tissue Antigens 2004; 63:1–12.
5. Williams PJ, Searle RF, Robson SC, Innes BA, Bulmer JN: Decidual leucocyte populations in early to late gestation normal human pregnancy. J Reprod Immunol 2009; 82:24–31.
6. Kammerer U, Schoppet M, McLellan AD, Kapp M, Huppertz HI, Kampgen E, Dietl J: Human decidua contains potent immunostimulatory CD83(+) dendritic cells. Am J Pathol 2000; 157:159–169.
7. Kammerer U, Eggert AO, Kapp M, McLellan AD, Geijtenbeek TB, Dietl J, van Kooyk Y, Kämpgen E: Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of early human pregnancy. Am J Pathol 2003; 162:887–896.
8. Blois SM, Kammerer U, Alba Soto C, Tometten MC, Shaikly V, Barrientos G, Jurd R, Rukavina D, Thomson AW, Klapp BF, Fernández N, Arck PC: Dendritic cells: key to fetal tolerance? Biol Reprod 2007; 77:590–598.
9. Guerin LR, Prins JR, Robertson SA: Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update 2009; 15:517–535.
10. Chen J, Chen Z: The effect of immune microenvironment on the progression and prognosis of colorectal cancer. Med Oncol 2014; 31:82.
11. de la Cruz-Merino L, Barco-Sánchez A, Henao Carrasco F, Nogales Fernández E, Vallejo Benítez A, Brugal Molina J, Martínez Peinado A, Grueso López A, Ruiz Borrego M, Codes Manuel de Villena M, Sánchez-Margalet V, Nieto-García A, Alba Conejo E, Casares Lagar N, Ibáñez Martínez J: New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol 2013; 13:785317.
12. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH: Tumor infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 2013; 36:224–231.
13. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H: The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67:425; author reply 426.
14. Nagaraj S, Gabrilovich DI: Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008; 68:2561–2563.
15. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162–174.
16. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V: Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319:47–65.
17. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P: PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463–7470.
18. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49–59.
19. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI: Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791–5802.
20. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233–4244.
21. Filipazzi P, Huber V, Rivoltini L: Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61:255–263.
22. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S: Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 2012; 35:107–115.
23. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S: Lung cancer patients’ CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008; 57:1493–1504.
24. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F: Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50:799–807.
25. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R: Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335–4345.
26. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S: Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2012; 130:1109–1119.
27. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V: Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238–244.
28. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678–689.
29. Munder M: Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009; 158:638–651.
30. Raber P, Ochoa AC, Rodriguez PC: Metabolism of L-arginine bymyeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41:614–634.
31. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI: Antigenspecific inhibition of CD8 + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989–999.
32. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM: Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689–695.
33. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044–3048.
34. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand- Rosenberg S: Myeloid-derived suppressor cells down-regulate Lselectin expression on CD4 + and CD8 + T cells. J Immunol 2009; 183:937–944.
35. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand- Rosenberg S: Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68–77.
36. Jia W, Jackson-Cook C, Graf MR: Tumor-infiltrating, myeloidderived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J Neuroimmunol 2010; 223:20–30.
37. Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762–774.
38. Serafini P, Mgebroff S, Noonan K, Borrello I: Myeloid-derived suppressor cells promote cross tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439–5449.
39. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ: The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138:105–115.
40. Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, Vuillefroy de Silly R, Usal C, Smit H, Martinet B, Thebault P, Renaudin K, Vanhove B: Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180:7898–7906.
41. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O’Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, Swan R, Chung CS, Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J, Laface D, Heyworth PG, Clare-Salzler M, Moldawer LL: MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204:1463–1474.
42. Tu Z, Li Y, Smith D, Doller C, Sugita S, Chan CC, Qian S, Fung J, Caspi RR, Lu L, Lin F: Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53:959–966.
43. Fainaru O, Paz G, Hantisteanu S, Hallak M: Myeloid cell alterations in the mouse placenta precede the onset of labor and delivery. Am J Obstet Gynecol 2014; 210:73e71–73e77.
44. Zhao H, Kalish F, Schulz S, Yang Y, Wong RJ, Stevenson DK: Unique roles of infiltrating myeloid cells in the murine uterus during early to midpregnancy. J Immunol 2015; 194:3713–3722.
45. Nair RR, Sinha P, Khanna A, Singh K: Reduced Myeloid-derived Suppressor Cells in the Blood and Endometrium is Associated with Early Miscarriage. Am J Reprod Immunol 2015; 73:479–486.
46. Köstlin N, Kugel H, Spring B, Leiber A, Marmé A, Henes M, Rieber N, Hartl D, Poets CF, Gille C: Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur J Immunol 2014; 44:2582–2591.
47. Rieger L, Segerer S, Bernar T, Kapp M, Majic M, Morr AK, Dietl J, Kammerer U: Specific subsets of immune cells in human decidua differ between normal pregnancy and preeclampsia–a prospective observational study. Reprod Biol Endocrinol 2009; 7:132.
48. Bernard A, Gelin C, Raynal B, Pham D, Gosse C, Boumsell L: Phenomenon of human T cells rosetting with sheep erythrocytes analyzed with monoclonal antibodies. “Modulation” of a partially hidden epitope determining the conditions of interaction between T cells and erythrocytes. J Exp Med 1982; 155:1317–1333.
49. Kammerer U, Gires O, Pfetzer N, Wiegering A, Klement RJ, Otto C: TKTL1 expression in human malign and benign cell lines. BMC Cancer 2015; 15:2.
50. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009; 9:188.
51. Segerer S, Kammerer U, Kapp M, Dietl J, Rieger L: Upregulation of chemokine and cytokine production during pregnancy. Gynecol Obstet Invest 2009; 67:145–150.
52. Haas JP: Home made ECL. Lab J 2005; T81: (http://www.laborjournal.de/rubric/tricks/tricks/trick81.lasso).
53. Talmadge JE, Gabrilovich DI: History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739–752.
54. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144:646–674.
55. Holtan SG, Creedon DJ, Haluska P, Markovic SN: Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009; 84:985–1000.
56. Carter AM: Comparative studies of placentation and immunology in non-human primates suggest a scenario for the evolution of deep trophoblast invasion and an explanation for human pregnancy disorders. Reproduction 2011; 141:391–396.
57. Dekel N, Gnainsky Y, Granot I, Racicot K, Mor G: The Role of Inflammation for a Successful Implantation. Am J Reprod Immunol 2014; 72:141–147.
58. Arck PC, Hecher K: Fetomaternal immune cross-talk and its consequences for maternal and offspring’s health. Nat Med 2013; 19:548–556.
59. Khaled YS, Ammori BJ, Elkord E: Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol 2013; 91:493–502.
60. Serafini P: Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res 2013; 57:172–184.
61. Houser BL, Tilburgs T, Hill J, Nicotra ML, Strominger JL: Two unique human decidual macrophage populations. J Immunol 2011; 186:2633–2642.
62. Svensson-Arvelund J, Ernerudh J: The role of macrophages in promoting and maintaining homeostasis at the fetal-maternal interface. Am J Reprod Immunol 2015; 74:100–109.
63. Fainaru O, Hantisteanu S, Hallak M: Immature myeloid cells accumulate in mouse placenta and promote angiogenesis. Am J Obstet Gynecol 2011; 204:544 e518–544 e523.
64. Mei-Dan E, Fainaru O, Hantisteanu S, Shavit T, Ellenbogen A, Hallak M: Proangiogenic immature myeloid cells populate the human placenta and their presence correlates with placental and birthweight. Am J Obstet Gynecol 2012; 207:141 e141–141 e145.
65. Ingman K, Cookson VJ, Jones CJ, Aplin JD: Characterisation of Hofbauer cells in first and second trimester placenta: incidence, phenotype, survival in vitro and motility. Placenta 2010; 31:535–544.
66. Tang Z, Abrahams VM, Mor G, Guller S: Placental Hofbauer cells and complications of pregnancy. Ann N Y Acad Sci 2011; 1221:103–108.
67. Tang Z, Tadesse S, Norwitz E, Mor G, Abrahams VM, Guller S: Isolation of Hofbauer cells from human term placentas with high yield and purity. Am J Reprod Immunol 2011; 66:336–348.
68. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells. J Immunol 2001; 166:5398–5406.
69. Nagaraj S, Youn JI, Gabrilovich DI: Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol 2013; 191:17–23.
70. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S: Complexity and challenges in defining myeloidderived suppressor cells. Cytometry B Clin Cytom 2015; 88:77–91.
71. Greten TF, Manns MP, Korangy F: Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11:802–807.
72. Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, Takikawa O, Saito S: IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 2005; 11:865–870.
73. Saito S, Shima T, Nakashima A, Shiozaki A, Ito M, Sasaki Y: What is the role of regulatory T cells in the success of implantation and early pregnancy? J Assist Reprod Genet 2007; 24:379–386.
74. Bronte V, Zanovello P: Regulation of immune responses by Larginine metabolism. Nat Rev Immunol 2005; 5:641–654.
75. Ishikawa T, Harada T, Koi H, Kubota T, Azuma H, Aso T: Identification of arginase in human placental villi. Placenta 2007; 28:133–138.
76. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, Fuentes JM, Bangham CR, Taylor GP, Herath S, Choi BS, Soler G, Teoh T, Modolell M, Muller I: Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol 2007; 37:935–945.
77. Haddad EK, Duclos AJ, Baines MG: Early embryo loss is associated with local production of nitric oxide by decidual mononuclear cells. J Exp Med 1995; 182:1143–1151.
78. Kakui K, Sagawa N, Itoh H, Yura S, Korita D, Takemura M, Nuamah MA, Fujii S: Expression of nitric oxide synthase isoforms in the human placenta is not altered by labor. Endocr J 2003; 50:535–544.
79. Sengupta J, Dhawan L, Lalitkumar PG, Ghosh D: Nitric oxide in blastocyst implantation in the rhesus monkey. Reproduction 2005; 130:321–332.
80. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V: Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22–35.
81. Lechner MG, Liebertz DJ, Epstein AL: Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185:2273–2284.
82. Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S: Tumor-induced myeloid-derived suppressor cell function is independent of IFNgamma and IL-4Ralpha. Eur J Immunol 2012; 42:2052–2059.
83. Bronte V, Gabrilovich DI: 2010; http://www.nature.com/nri/posters/mdscs/index.html.
84. Lee JY, Lee M, Lee SK: Role of endometrial immune cells in implantation. Clin Exp Reprod Med 2011; 38:119–125.
85. Mor G, Cardenas I, Abrahams V, Guller S: Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 2011; 1221:80–87.
86. Sykes L, MacIntyre DA, Yap XJ, Teoh TG, Bennett PR: The Th1: th2 dichotomy of pregnancy and preterm labour. Mediators Inflamm 2012; 2012:967629.
87. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T: Tumorinfiltrating myeloid-derived suppressor cells are pleiotropicinflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008; 83:1136–1144.
88. Engert S, Rieger L, Kapp M, Becker JC, Dietl J, Kammerer U: Profiling chemokines, cytokines and growth factors in human early pregnancy decidua by protein array. Am J Reprod Immunol 2007; 58:129–137.
89. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P: MDSC as a mechanism of tumor escape from sunitinib mediated antiangiogenic therapy. Int Immunopharmacol 2011; 11:856–861.
90. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH: Gr-1 + CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123–1131.
91. Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, Lin PC: Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 2011; 6:e18534.
92. Chen HW, Chen HY, Wang LT, Wang FH, Fang LW, Lai HY, Chen HH, Lu J, Hung MS, Cheng Y, Chen MY, Liu SJ, Chong P, Lee OK, Hsu SC: Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth regulated oncogene chemokines. J Immunol 2013; 190:5065–5077.
93. Derive M, Bouazza Y, Alauzet C, Gibot S: Myeloid-derived suppressor cells control microbial sepsis. Intensive Care Med 2012; 38:1040–1049.
94. Heikkinen J, Mottonen M, Komi J, Alanen A, Lassila O: Phenotypic characterization of human decidual macrophages. Clin Exp Immunol 2003; 131:498–505.
95. Schmid MC, Varner JA: Myeloid cells in tumor inflammation. Vasc Cell 2012; 4:14.
96. Balkwill F: Chemokine biology in cancer. Semin Immunol 2003; 15:49–55.
97. Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29:313–326.
98. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404:407–411.
99. Xu X, Wang Q, Deng B, Wang H, Dong Z, Qu X, Kong B: Monocyte chemoattractant protein-1 secreted by decidual stromal cells inhibits NK cells cytotoxicity by up-regulating expression of SOCS3. PLoS One 2012; 7:e41869.
100. Piccinni MP: Role of T-cell cytokines in decidua and in cumulus oophorus during pregnancy. Gynecol Obstet Invest 2007; 64:144–148.
101. Tsuda H, Michimata T, Hayakawa S, Tanebe K, Sakai M, Fujimura M, Matsushima K, Saito S: A Th2 chemokine, TARC, produced by trophoblasts and endometrial gland cells, regulates the infiltration of CCR4+ T lymphocytes into human decidua at early pregnancy. Am J Reprod Immunol 2002; 48:1–8.